Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis

The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and phase 3 HERCULES trials. Integrated analysis of data from both trials was conducted to increase statistical power for assessing treatment dif...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Adv
Main Authors: Peyvandi, Flora, Cataland, Spero, Scully, Marie, Coppo, Paul, Knoebl, Paul, Kremer Hovinga, Johanna A., Metjian, Ara, de la Rubia, Javier, Pavenski, Katerina, Minkue Mi Edou, Jessica, De Winter, Hilde, Callewaert, Filip
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2021
Fag:
Stimulus Report
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8095153/
https://ncbi.nlm.nih.gov/pubmed/33881463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001834
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker